Studies
First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS viral oncogene homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
Cancer
Internal Medicine
Colorectal Cancer
Sarcoma
Brain and Spinal Cord Cancer
Pancreatic Cancer
Adult Subjects
Female Subjects
Male Subjects
This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides 7P\]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.
Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Pancreatic Cancer
Cancer
Internal Medicine
Pancreatic Cancer
Adult Subjects
Female Subjects
Male Subjects
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.